How many approved Hidradenitis Suppurativa treatments are there?

Currently, in the USA there are two biologic treatments approved for moderate-to-severe Hidradenitis Suppurativa. 

Humira (adalimumab) and Cosentyx (Secukinumab).

Approval for Bimzelx (Bimekizumab), a biologic, is anticipated in late 2024 or early 2025, if all goes well. 

Several clinical trials are currently underway, and some hold great potential for the future. 

Tidbit:

Effective treatment options have been discovered by identifying the sources of inflammatory markers thought to be associated with HS symptoms. Even though classified as biologics, these medications work differently within the body to treat hidradenitis.

Bimzelx and Cosentyx both target IL-17 (but in distinct ways).

Bimekizumab selectively ‘inhibits both IL-17A and IL-17F

Cosentyx targets and blocks IL-17A.

Humira targets and blocks TNF-alpha

_{I will go into this topic more thoroughly including countries of drug approval and some history in the future in my article. It will be tagged to this section. Including tips on how to better manage.}

_{The tidbit in this FAQ was inspired by Michael Duguay (HS Warrior).}

_{Special Note: Researched, compiled, and written by Denise Fixsen. This information is backed by my 46 years of living with Hidradenitis Suppurativa, 10 years of dealing with multiple chronic illnesses, 36 years of advocacy, and continuous education. And to ensure accuracy, reliability, and trustworthiness, I incorporate peer-reviewed studies and other high-quality sources into my articles and material. I also wanted to inform you that I’ve chosen to end my collaboration with editors on my articles. Although there may be grammar errors due to brain illnesses (mostly), with this said, my content remains reliable, factual, and solid.}

_{Medical Disclaimer: This content is solely for information, education, and support. The purpose is not to serve as a replacement for professional medical advice, diagnosis, or treatments.}

_{Sources: PMCID: PMC10609891 doi: 10.1111/exd.14619PMCID: PMC8183777}

_{FAQ posted on 09-10-2024}